OPTIMIZERX CORP. DL-,001

OptimizeRx reported adjusted EPS of $0.16 for Q2 2026 versus the consensus expectation of $0.10 and revenue of $20.5 million, which was 30% below the prior year. Management reaffirmed the full-year outlook of $95–100 million in revenue and adjusted EBITDA of $21–25 million and emphasized the shift to a broader software- and platform-based model for pharma marketers. Despite improved profitability, investors viewed the high customer concentration and declining revenue negatively, sending the shares lower after hours. The company reduced debt, maintains high gross margins, and plans strategic integrations and new product launches to drive recurring revenue. » Más en de.investing.com

The board of directors of OptimizeRx has appointed Andy D’Silva as chief financial officer and Heather Favazza as chief accounting officer; both appointments take effect on January 1, 2027. D’Silva succeeds Ed Stelmakh, who will continue to serve as chief financial & strategy officer through the end of 2026 and will support the company as strategic advisor through the end of 2027. Favazza previously served eight years as corporate controller and will be responsible for operational accounting, financial reporting, internal controls and compliance. The company emphasizes that the appointments are part of succession planning and that its financial and growth strategy remains unchanged. » Más en de.investing.com

OptimizeRx’s stock rose premarket after unveiling CopayCue, a technology that embeds manufacturer discounts and copay cards in real time into the electronic prescribing process. CopayCue leverages prescribing intents from medical staff via a network of more than 400 EHR and e-prescribing platforms and automatically sends savings offers to the pharmacy. The product is intended to improve medication affordability and reduce prescription abandonment; initial data show a prescription volume increase of 4–5% versus EHR banners alone (11.5% for standalone programs). » Más en de.investing.com

OptimizeRx reported Q1 2026 EPS of $0.14 (forecast $0.01) and revenue of $19.8 million (forecast $18.86 million), triggering a 2.42% share price increase. Adjusted EBITDA rose 120% to $3.3 million, cash on hand was $20.2 million, and debt was reduced by $2.7 million. The company is placing greater emphasis on subscription-based revenues and AI solutions and expects EPS of $0.18 for Q2 and $0.96 for full-year 2026. » Más en de.investing.com

OptimizeRx beat expectations in Q4 2025 with EPS of $0.51 (expectation $0.22) and revenue of $32.2 million (expectation $31.46 million). Gross margin rose to a record 74.8%, but the company expects a normalization in 2026 to the mid-60 percent range. Despite the results, the stock fell about 14.36% in after-hours trading and closed at $6.74. » Más en de.investing.com